Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Study to Evaluate Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Primary or Secondary Myelofibrosis

NCT06517875 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06517875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06517875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Study to Evaluate Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Primary or Secondary Myelofibrosis
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Recruiting
Start date
February 28, 2025
Completion date
March 17, 2028
Enrollment
68 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis; primary myelofibrosis; post-polycythemia vera myelofibrosis; post-essential thrombocythemia myelofibrosis, primary myelofibrosis